PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients. RESEARCH DESIGN AND METHODS: This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA1c. The confirmatory secondary end point was change from baseline to week 26 in body weight. RESULTS: In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA1c 8.0% [64 mmol/mol]), oral semaglutide reduced HbA1c (placebo-adjusted treatment differences at week 26: treatment policy estimand, −0.6% [3 mg], −0.9% [7 mg], and −1.1% [14 mg]; trial product estimand, −0.7% [3 mg], −1.2% [7 mg], and −1.4% [14 mg]; P < 0.001 for all) and body weight (treatment policy, −0.1 kg [3 mg], −0.9 kg [7 mg], and −2.3 kg [14 mg, P < 0.001]; trial product, −0.2 kg [3 mg], −1.0 kg [7 mg, P = 0.01], and −2.6 kg [14 mg, P < 0.001]). Mild-to-moderate transient gastrointestinal events were the most common adverse events with oral semaglutide. Trial product discontinuations occurred in 2.3–7.4% with oral semaglutide and 2.2% with placebo. CONCLUSIONS: In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA1c (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapies shown to positively affect albuminuria and declining eGFR include ACE inhibitors, ARBs, SGLT2is, GLP-1 RAs, and the nonsteroidal mineralocorticoid antagonist finerenone.197,209,239,242,393,423–435”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin and canagliflozin demonstrated reduction in MACE in CVOTs; empagliflozin also demonstrated decreased CV death and all-cause mortality.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have shown a decrease in hospitalization for HF in their CVOTs.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Dapagliflozin based on the DAPA-CKD RCT424 has received an FDA indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization for HF in adults with CKD at risk of progression.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Multiple studies have shown renal and CV benefits of SGLT2is239,424–426,444,1052–1054”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†Severe hypoglycemia was defined according to the American Diabetes Association classification (16) (requiring assistance of another person to actively administer carbohydrateor glucagonor takeother correctiveactions).”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 2×
“The safety profile of oral semaglutide was generally consistent with that reported for subcutaneous semaglutide (19)”
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Cited by
Items 201–300 of 538
Jeromson, S., Baranowski, B., Akcan, M., Waters, B. D., Eisner, K., Bellucci, A., Trang, S., Abolhassani, A., Tello‐Palencia, M. A., Schweitzer, A. M., et al. (2025) · The Journal of Physiology · doi:10.1113/jp289449 · Cited by 23
Le, T. T. B., Minh, L. H. N., Devi, P., Islam, N., & Sachmechi, I. (2024) · Cureus · doi:10.7759/cureus.51460 · Cited by 20
Cersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 17
Fiore, V., Carbotta, G., Barraco, S., Falasca, P., Aricò, C. N., & Barucca, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16174 · Cited by 17
“Similarly, in the PIONEER REAL Japan study, Yabe et al 44 reported a 0.5% reduction in HbA1c levels in adults aged 75 years and older over a period of 34 – 44 weeks.”
InfluentialJohansson, K. S., Sonne, D. P., Knop, F. K., & Christensen, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1791078 · Cited by 17
Kakouri, A., Kanti, G., Kapantais, E., Kokkinos, A. D., Lanaras, L., Farajian, P., Galanakis, C., Georgantopoulos, G., Vlahos, N., Mastorakos, G. P., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14090869 · Cited by 18
Pohl, M., Baumann, L., Behnisch, R., Kirchner, M., Krisam, J., & Sander, A. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0373 · Cited by 24
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
Mosenzon, O., Miller, E. M., & Warren, M. L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1800286 · Cited by 16
Nauck, M. A., & Horowitz, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01201-1 · Cited by 16
Pinto, M., Brennan, L., Diehl, K., Lin, S., & Heacock, S. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241289959 · Cited by 18
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
“Semaglutide, a newer GLP-1RA, was initially approved by the United States FDA in 2017 for the treatment of type 2 diabetes [5].”
Liarakos, A. L., & Koliaki, C. C. (2023) · Biomedicines · doi:10.3390/biomedicines11071875 · Cited by 16
Kim, J. S., Lee, G., Park, K., & Oh, S. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0421 · Cited by 19
“Compared to previous meta-analyses [25,26] our meta-analysis included more recent studies on semaglutide (Peptide Innovation for Early Diabetes Treatment [PIONEER] 1 and PIO-NEER 5) [41,42].”
ResultFormichi, C., Baronti, W., Gennaro, G., Ceroni, M. C., Nigi, L., Rizzo, L., & Dotta, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02369-4 · Cited by 17
“Its efficacy, in terms of improving glycemic control and BW, and safety has been demonstrated in the Peptide Innovation for Early Diabetes Treatment (PIONEER) study program [17–20].”
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Saravanan, P., Bell, H. K., Braae, U. C., Collins, E., Deinega, A., Dhatariya, K., Machell, A., Trent, A., & Strzelecka, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02973-z · Cited by 16
Sandmeier, M., Ricci, F., To, D., Lindner, S., Stengel, D., Schifferle, M., Koz, S., & Bernkop‐Schnürch, A. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01729-0 · Cited by 18
“Even though oral sema-glutide showed impressive efficacy in various trials [ 20, 21], the overall bioavailability is just around 1%, indicating much room for improvements to reduce the cost per dose [16, 19].”
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
Exploring beyond numeric weight loss: The metabolic effects of semaglutide
Sokary, S., & Bawadi, H. A. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.03.010 · Cited by 19
Chiang, C., Chang, Y., Yu, C.-C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S., Chiang, C.-H., Lake, L. L., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.020 · Cited by 15
Ahmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 18
“…Wadden et al [35] Semaglutide Placebo 306 407 75.2% 55 204 27.0% Wilding et al [36] Semaglutide Placebo 1128 1306 86.4% 206 655 31.4% Aroda et al [22] Semaglutide Placebo 47 175 26.9% 27 178 15.2% GLP-1 = glucagon-like peptide-1. www.md-journal.com Inagaki et al found that 61% of the individuals…”
InfluentialSeijas‐Amigo, J., Salgado‐Barreira, Á., Castelo-Dominguez, R., Pérez-Álvarez, M. T., Ponce-Piñón, B., Fernández-Silva, M., Rodríguez-Barreiro, M., Pereira-Pía, M., Iglesias-Moreno, J. M., Gago-García, M., et al. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2023.05.004 · Cited by 15
A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants
Nielsen, M. S., Brøndsted, L., Kankam, M. K., Morelli, G., Nguyen, D., Skjøth, T. V., Patted, U. R. H., & van Hout, M. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01674-8 · Cited by 15
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & Skolnik, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14
Yeung, A. W. K., Hammerle, F. P., Behrens, S., Matin, M., Mickael, M., Litvinova, O., Parvanov, E. D., Kletečka-Pulker, M., & Atanasov, A. G. (2025) · JMIR Infodemiology · doi:10.2196/59767 · Cited by 15
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
Seidu, S., Mellbin, L., Kaiser, M., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.07.011 · Cited by 14
Li, W. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521500289 · Cited by 16
Mayer, C. S., & Fontelo, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15911 · Cited by 12
“…the clinical trials leading to US Food and Drug Administration approval (Pivotal Trials) associated with semaglu-tide (NCT02054897 for Ozempic and NCT02906930 for Rybelsus) for people with type 2 diabetes, 11 – 14 our evaluation also showed decreases in HbA1c, but to a lesser extent than in trials.”
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Chan, M. K., Dimitriou, A., & Lam, S. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000351 · Cited by 14
Eliasson, B., Ericsson, Å., Fridhammar, A., Nilsson, A., Persson, S., & Chubb, B. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00317-z · Cited by 14
Sadraei, S., Aarabi, A., Firouzabadi, S. R., Alinejadfard, M., Mohammadi, I., & Jolfayi, A. G. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05278-3 · Cited by 13
Podder, D., Stala, O., Miah, A., Agyapong, A., Moore, M. E., Hirani, R., Diegisser, D., Garcia, V. G., & Etienne, M. (2026) · Diabetology · doi:10.3390/diabetology7030046 · Cited by 19
Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
Masson, W. M., Lobo, M., Barbagelata, L., Cobo, A. L., & Nogueira, J. P. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.01.001 · Cited by 26
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
Purcell, A. R., Zhen, X. M., Wong, J., & Glastras, S. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70188 · Cited by 13
Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
Gorst‐Rasmussen, A., & Tarp-Johansen, M. J. (2022) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2022.2058525 · Cited by 15
“PIONEER 1 was a parallel-group, phase 3 randomized clinical trial of the efficacy and safety of the glucagon-like peptide 1 (GLP-1) receptor agonist oral semaglutide in comparison with placebo in people with type 2 diabetes (Aroda et al. 2019) (ClinicalTrials.gov identifier NCT02906930).”
MethodAdvances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Lavernia, F., & Blonde, L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798638 · Cited by 13
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Liu, Y., & Luo, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0873-2 · Cited by 15
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
“The impacts of Semaglutide on glycemic control and body weight reduc - tion have been demonstrated in different clinical trials [ 75 , 76 , 242 ].”
InfluentialAa, B., Serova, M., Chashkina, M. I., Kosharnaia, R. S., Salpagarova, Z. K., Andreev, D. A., & Giverts, I. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.06 · Cited by 13
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
The Effective Use of Anti-obesity Medications
Schmitz, S. H., & Aronne, L. J. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.003 · Cited by 13
Suzuki, R., Amadid, H., Major‐Pedersen, A., & Yabe, D. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14219 · Cited by 12
“The PIO-NEER phase 3 program demonstrated oral semaglutide superiority vs placebo and superiority or non-inferiority vs active comparators in reducing glycated hemoglobin (HbA 1c ) and body weight in adults with type 2 diabetes, with a safety pro fi le consistent with the GLP-1RA class 19 – 25 .”
BackgroundBALDASSARRE, M. P. A., Dalmazi, G. D., Coluzzi, S., Carrieri, F., Febo, F., Centorame, G., Cassino, P., Piacentino, L., Baroni, M. G., Consoli, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113054 · Cited by 13
Xie, P., Abildlund, M. T., Bækdal, T. A., He, X., Lyauk, Y. K., Patted, U. R. H., Zu, N., & Shi, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15624 · Cited by 14
“16 – 25 Currently, all GLP-1RAs available in China are administered via subcutaneous injection 3 ; therefore, the development of an oral GLP-1RA represents a new convenient treatment option for people with T2D in China.”
Candido, R., Loreto, C. D., Desenzani, P., Pantanetti, P., Romano, C., Settembrini, S., Solerte, S. B., & Fadini, G. P. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01625-3 · Cited by 14
Pantanetti, P., Ronconi, V., Sguanci, M. E., Palomares, S. M., Mancin, S., Tartaglia, F. C., Cangelosi, G., & Petrelli, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164752 · Cited by 12
“…extensive phase 3 clinical testing: the PIONEER program (Peptide Innovation for Early diabetes treatment) comprised trials comparing once-daily oral semaglutide with a placebo or active comparators in different populations [16–24], also including a Cardiovascular Outcome Trial (CVOT) [25].”
MethodAraki, E., Terauchi, Y., Watada, H., Deenadayalan, S., Christiansen, E., Horio, H., & Kadowaki, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14536 · Cited by 14
“ETDs between oral semaglutide and comparators were generally similar for Japanese subgroups compared with the overall populations in these trials.(8,10,11,15) In the prospective, Japanese PIONEER 9 and 10 trials, week 26 reductions from baseline in HbA1c (1.”
BackgroundMethodResultSelf-citationComparing medication persistence with oral and subcutaneous semaglutide in a real-world setting
Conti, M., Pontiggia, L., Vergani, M., Muraca, E., Cannistraci, R., Perra, S., Lattuada, G., Perseghin, G., & Ciardullo, S. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02424-9 · Cited by 12
“In PIONEER-6, the cardiovascular outcome trial (CVOT) of the programme, oral semaglutide treatment reached non-inferiority to placebo, showing a non-signifi - cant trend towards a lower incidence of first MACE and a significantly lower incidence of CV-related death and all-cause death [13– 19 ].”
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037510 · Cited by 12
“18,19 Mechanisms for this cardioprotective effect of GLP1-RA include not only improved glycemic control and weight loss 29 but also blood pressure reduction, 19 anti-inflammatory effects, 30 and direct cardioprotection.”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Hong, B., Kim, H., Lee, D., & Kim, K. (2025) · Pharmaceuticals · doi:10.3390/ph18071058 · Cited by 11
“…the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) [10], Peptide Innovation for Early Diabetes Treatment (PIONEER) [11], and Semaglutide Treatment Effect in People with Obesity (STEP) [12] trials—have highlighted its superiority in glycemic control and weight…”
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Wu, R., Xing, B., Huang, Y., Zhou, Z., Sun, B., Yu, L., & Wang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554795 · Cited by 11
Singh, A. K., Singh, R., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102436 · Cited by 13
Koufakis, T., Maltese, G., & Kotsa, K. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106443 · Cited by 12
Shabutdinova, O. R., Dautov, A. R., Samkov, A. A., Kononenko, A. V., Sargaliev, A. F., Davletshin, A. R., Andresova, P. A., Zarbeeva, K. R., Torshkhoeva, D. A., Rakhmonkulov, U. A., et al. (2023) · Problems of Endocrinology · doi:10.14341/probl13197 · Cited by 17
Dang, L. E., Fong, E., Tarp, J. M., Clemmensen, K. K. B., Ravn, H., Kvist, K., Buse, J. B., van der Laan, M. J., & Petersen, M. L. (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2023.656 · Cited by 14
“Oral semaglutide was later developed and shown to decrease glycated hemoglobin (HbA1c) and body weight compared to placebo [12] and multiple medications [13 – 15].”
BackgroundProhibitions in the meta-inflammatory response: a review
Тодосенко, Н. М., Yurova, K. A., Vulf, M. A., Хазиахматова, О. Г., & Litvinova, L. S. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1322687 · Cited by 11
When Should the Treatment of Obesity in Thyroid Disease Begin?
Sutkowska, E., Kisiel, M., & Zubkiewicz‐Kucharska, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010157 · Cited by 11
Wełnicki, M. T., Gorczyca-Głowacka, I., Mamcarz, A., Filipiak, K. J., Wożakowska−Kapłon, B., Barylski, M., Szymański, F. M., Kasprzak, J. D., Grabowski, M., & Dzida, G. J. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0282 · Cited by 15
Semaglutide injection for the treatment of adults with type 2 diabetes
Chudleigh, R. A., & Bain, S. C. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1776108 · Cited by 12
Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Hicks, D., Brown, P., Yousef, Z., Dashora, U., Viljoen, A., Beba, H., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01201-z · Cited by 10
Lütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0469 · Cited by 10
“In contrast, orforglipron, lacking a peptide in its chemical formulation, does not require such precautions to enhance absorption and may be a potential alternative in obesity treatment (7,11,29).”
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Hurwitz, M., Agboola, O. J., Gami, A., Williams, M. S., Virani, S. S., Sharma, G. V., & Patel, J. (2025) · US Cardiology Review · doi:10.15420/usc.2024.33 · Cited by 10
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
Chakravarthy, M. V., Elliott, M. A., Acosta, L., Sonnenberg, G. E., Bialonczyk, D., Wu, J., ARGÜELLES-TELLO, F. A., Garcia‐Reza, R., González‐González, J. G., Hansen, S. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70006 · Cited by 11
“28,29 Weight loss effects are more centrally mediated than glucose homeostasis effects and consequently tend to require higher doses of medication.”
Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations
Kim, D.-H., & Kim, J.-E. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00762-6 · Cited by 10
Joy, B., Ramsamooj, A., Ibrahim, S., Wen, J., Hsu, N., & Frezza, E. (2026) · Endocrine · doi:10.1007/s12020-025-04494-3 · Cited by 13
Wu, T., Wong, C. K. H., Lui, D. T. W., Wong, S. K., Lam, C. L. K., Chung, M. S. H., McAllister, D., Welbourn, R., & Dixon, J. B. (2023) · BJS Open · doi:10.1093/bjsopen/zrad077 · Cited by 12
Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus
Orime, K., & Terauchi, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1803280 · Cited by 13
Self-citationEffects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis
Rebelo, T. G., de Araujo Paysano, M. L. B., Matheus, G. T. F. U., Ribeiro, D. M., Said, T. B., & Kelly, F. A. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133683 · Cited by 9
Pandey, R. K., Jan, M., Mohammad, A., Jawaid, K. A., Naveed, M., Abid, M. A., Amir, A. B., Ahmed, S., Safiullah, M., Bhatti, M. I., et al. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70134 · Cited by 9
“%) and other GLP-1 receptor agonists [40].”
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Mertens, J., Winter, H. T. D., Dirinck, E. L., Francque, S., & Block, C. E. M. D. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251362497 · Cited by 12
The Estimand Framework and Causal Inference: Complementary Not Competing Paradigms
Drury, T., Bartlett, J. W., Wright, D., & Keene, O. N. (2025) · Pharmaceutical Statistics · doi:10.1002/pst.70035 · Cited by 9
“The PIONEER 1 trial compared oral semaglutide to placebo in adult patients with type 2 diabetes, with a primary endpoint of change from baseline HbA1c [13].”
Sillassen, C. D. B., Petersen, J. J., Faltermeier, P., Yucel, D., Siddiqui, F., Andersen, R. K., Graever, L., Bjerg, J. L., Kamp, C. B., Grand, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04486-0 · Cited by 10
“Non-serious adverse events were reported as outcomes in 45 trials [33–41, 43–46, 48–56, 58–67, 69–73, 75–79, 81, 82].”
InfluentialAl-Dahi, W. A., Alenezi, A., Alessa, T., Alhamdan, R., Al-Humood, K., Alqallaf, A., AlOtaibi, T. M., AlRajab, H., Alshammari, A. M., Alyousef, A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01838-0 · Cited by 9
Overgaard, R. V., Birkhan, O. A., Rathor, N., Sparsø, T., Strathe, A., Wharton, S., & Rubino, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70769 · Cited by 9
Morga, A., Latimer, N. R., Scott, M., Hawkins, N., Schlichting, M., & Wang, J. (2022) · Value in Health · doi:10.1016/j.jval.2022.08.008 · Cited by 9
Shen, S., Liao, Q., Gu, L., Zhu, Y., Liu, Y., Zhang, X., Zhang, J., Shi, Q., Sun, Y., Wang, J., et al. (2024) · Acta Materia Medica · doi:10.15212/amm-2023-0041 · Cited by 13
“Despite clinical success, GLP-1 receptor peptide agonists are suboptimal due to administration and side effect profiles, including nausea and vomiting [52].”
BackgroundBeyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics
Osaka, H., Nishida, K., & Kanazawa, T. (2024) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.185 · Cited by 12
“30 Hydralazine (hydrochloride) Hydralazine, a vasodilator acting directly on vascular smooth muscle, is primarily used in treating hypertension.”
BackgroundEfficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis
Zhang, L., Hua, Z., Fang, Z., Wei, J., & Yang, L. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2483 · Cited by 12
“Six studies 14,17–19, 21, 22 reported changes in HbA1c compared to placebo, and statistical heterogeneity heterogeneity was Six studies 15–17, 20, 22, 23 reported a reduction in HbA1c compared to positive control drugs, FPG.”
Berković, M. C., Režić, T., Bilić-Čurčić, I., & Mrzljak, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i20.6759 · Cited by 10
Meier, J. J., Bardtrum, L., CHENG, A. Y. Y., Malling, B., Montanya, E., Wagner, L., & Pratley, R. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14957 · Cited by 9
“2% of patients treated with oral semaglutide experienced GI AEs, including nausea, diarrhoea or vomiting.(8-14) We sought to assess whether the body weight loss observed with oral semaglutide in the PIONEER trials was attributable to GI AEs.”
BackgroundSemaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes
Blakely, K. K., & Weaver, K. (2020) · Nursing for Women s Health · doi:10.1016/j.nwh.2020.07.005 · Cited by 9
Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review
Sofogianni, A., & Τζιόμαλος, Κ. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01478-9 · Cited by 10
Nekidy, W. S. E., Hasan, H., Abidi, E., Sayegh, L. A., Dajani, R. Z., El-Kaissi, S., Hegazin, S. B., & Mallat, J. (2025) · Hospital Pharmacy · doi:10.1177/00185787251340645 · Cited by 8
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
Alwafi, H. H., Alharbi, S. S., Al-adwani, G. A., Alsanosi, S., Oyelade, T., Almalki, F., Thalib, H. I., Naser, A. Y., Alfahmi, M. Z., Alotaibi, B. J., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1639704 · Cited by 10
Niazi, S. K. (2026) · Frontiers in Drug Delivery · doi:10.3389/fddev.2026.1776167 · Cited by 8
“The recent approval of oral semaglutide represents the first unequivocal demonstration that a systemically acting peptide can be administered orally at a commercial scale with reproducible clinical benefit (Davies et al., 2017; Aroda et al., 2019).”
Petrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
Recent and Upcoming Therapies for Management of Type 2 Diabetes: A Review
Gokalani, R. A., Saiyed, M., Dey, A. K., & Sheikh, F. (2024) · Preventive Medicine Research & Reviews · doi:10.4103/pmrr.pmrr_12_24 · Cited by 8
Jordan, G., Young, S., & Alemán, J. O. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.006 · Cited by 11
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., PIONEER 1 Investigators, Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., Hudcova, M., Vesela, A., Rancova, A., Haluzik, M., Kiyosue, A., Matsuoka, O., Inoue, S., Terauchi, Y., Fukushima, Y., Ide, Y., Violante Ortiz, R. M., Morales Villegas, E., Golovach, A., Alpenidze, D., Frolova, E., Zhdanova, E., Ruyatkina, L., Ershova, O., Samoilova, Y., Zyangirova, S., Lalic, K., Lalic, N., Beljic Zivkovic, T., Ataoglu, E., Bakiner, O., Dayan, A., Sargin, M., Mert, M., Adas, M., Tabak, O., Altuntas, Y., Murray, A., Iranmanesh, A., Schlau, A., Wieskopf, B., Snyder, B., Griffin, C., Fogarty, C., Lovell, C., Allison, D., Fitz-Patrick, D., Grant, D., Klonoff, D., Williams, D., Armas, E., Palace, E., Ruoff, G., Martinez, G., Perez, G., Bays, H., Tatu, H., Maynard, J., Cedeno, J.-E., Aroda, V., Park, J., Sutton, J., Pouzar, J., Bertsch, J., Condit, J., Serje, J., Cabaccan, J., Risser, J., Frias, J., Rosenstock, J., Sivalingam, K., Maw, K., Hanson, L., Billings, L., Connery, L., Juarez, M., Lillestol, M., Fraser, N., Beckett, P., Wade, R., Gaona, R., Jackson, R., DeLuca, R., Alpizar, S., Herring, S., Stringam, S., Bauer, S., Gangi, S., Sligh, T., Jarrett, W., & Fitzgibbons, W.
- Affiliations
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Cardiometabolic Research Center, Aguascalientes, Mexico
- Novo Nordisk (Denmark) (DK)
- Institute for Clinical and Experimental Medicine and Institute for Endocrinology, Prague, Czech Republic
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-11
- Volume
- 42
- Issue
- 9
- Pages
- 1724-1732
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2951522032
- Cited by
- 493
- References
- 23
- Citations by year
- 2026: 60 · 2025: 107 · 2024: 91 · 2023: 56 · 2022: 53 · 2021: 55 · 2020: 57 · 2019: 13
- FWCI
- 36.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, GLP-1 receptor agonists, monotherapy, HbA1c, glycemic control, weight loss, treatment policy estimand, gastrointestinal adverse effects, drug discontinuation, dose comparison, treatment efficacy and safety
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Diet, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.